Table 3 Clinical and laboratory data from SCLC patients stratified by PLR
From: High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer
Variables | PLR ≤ 148 | PLR > 148 | p value | ||
|---|---|---|---|---|---|
n | n | ||||
Age (years, ±SD) | 58.54 ± 9.60 | 76 | 58.11 ± 11.52 | 63 | 0.811 |
Gender (male/female) | 60/16 | 76 | 47/16 | 63 | 0.552 |
Stage (LD/ED) | 43/33 | 76 | 13/50 | 63 | 0.000*** |
Metastasis (yes/no) | 56/20 | 76 | 52/11 | 63 | 0.212 |
Brain metastasis (yes/no) | 3/73 | 76 | 6/57 | 63 | 0.299 |
Bone metastasis (yes/no) | 4/72 | 76 | 11/52 | 63 | 0.021 |
Liver metastasis (yes/no) | 5/71 | 76 | 15/48 | 63 | 0.004 |
Adrenal metastasis (yes/no) | 6/70 | 76 | 8/55 | 63 | 0.349 |
Pleural metastasis (yes/no) | 4/72 | 76 | 8/55 | 63 | 0.120 |
Lymph node metastasis (yes/no) | 53/23 | 76 | 46/17 | 63 | 0.671 |
Mediastinal metastasis (yes/no) | 2/74 | 76 | 2/61 | 63 | 1.000 |
Smoking (never/ever) | 19/57 | 76 | 20/43 | 63 | 0.449 |
Smoking amount (BI) | 720 (400–980) | 55 | 680 (400–1200) | 43 | 0.725 |
Family cancer history (yes/no) | 16/31 | 47 | 11/29 | 40 | 0.511 |
Exposure to cooking fume (never/ever) | 27/19 | 46 | 12/24 | 36 | 0.022* |
Operation (yes/no) | 11/65 | 76 | 3/60 | 63 | 0.058 |
Radiotherapy (yes/no) | 39/37 | 76 | 22/41 | 63 | 0.052 |
Chemotherapy (yes/no) | 71/5 | 76 | 49/14 | 63 | 0.008** |
NLR | 2.59 (1.69–3.17) | 76 | 4.43 (2.88–5.50) | 63 | 0.000*** |
RBC (1012/L) | 4.57 (4.18–5.02) | 76 | 4.24 (3.74–4.57) | 63 | 0.000*** |
Hb (g/L) | 139 (126–149) | 76 | 124 (107–136) | 63 | 0.000*** |
MCV (fL) | 92.4 (89.1–95.7) | 76 | 90.1 (86.4–93.3) | 63 | 0.012* |
PLT (109/L) | 155 (130–192) | 76 | 226 (192–299) | 63 | 0.000*** |
WBC (109/L) | 6.45 (5.29–7.81) | 76 | 6.52 (5.15–7.57) | 63 | 0.828 |
Neutrophil (109/L) | 4.11 (3.02–5.20) | 76 | 4.64 (3.59–5.76) | 63 | 0.075 |
Lymphocyte (109/L) | 1.63 (1.32–2.00) | 76 | 1.08 (0.87–1.29) | 63 | 0.000*** |
Alb (g/L) | 41.8 (39.5–44.2) | 75 | 38.2 (34.8–41.2) | 61 | 0.000*** |
LDH (U/L) | 196 (176–239) | 73 | 219 (183–290) | 60 | 0.023* |
ALP (U/L) | 79 (66–93) | 75 | 78 (59–107) | 61 | 0.941 |
CHO (mmol/L) | 4.47 (4.09–4.96) | 73 | 4.15 (3.62–4.59) | 60 | 0.002** |
TG (mmol/L) | 1.27 (0.91–1.68) | 73 | 1.07 (0.82–1.43) | 60 | 0.115 |
HDL-C (mmol/L) | 1.24 (1.07–1.50) | 73 | 1.18 (0.98–1.49) | 60 | 0.144 |
LDL-C (mmol/L) | 2.65 (2.40–3.18) | 73 | 2.38 (2.08–2.82) | 60 | 0.003** |
CR (μmol/L) | 76.9 (70.9–89.0) | 75 | 69.2 (59.0–83.6) | 61 | 0.011* |
CEA (ng/ml) | 3.75 (1.90–8.21) | 60 | 3.61 (1.90–10.87) | 54 | 0.790 |
CYFRA21-1 (ng/ml) | 3.32 (2.33–4.94) | 51 | 3.35 (2.32–6.50) | 50 | 0.370 |
NSE (ng/ml) | 40.81 (19.22–82.20) | 60 | 48.65 (28.26–127.48) | 52 | 0.066 |